The Michigan Supreme Court will decide whether to overturn past precedent to clear the way for an attorney general probe into ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

A nonprofit founded by members of the Lilly family has been unloading Eli Lilly stock nearly every day since the start of the month.

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Among 91 women, those who used a closed-loop insulin delivery system spent an average of 65.4% of time in pregnancy-specific ...

Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, ...

Oct 15 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ...